New combo therapy shows promise for tough lung cancer
NCT ID NCT05482568
First seen Apr 24, 2026 · Last updated May 10, 2026 · Updated 4 times
Summary
This study tests a new drug called SHR-A1811 combined with either pyrotinib or SHR-1316 in people with advanced HER2-positive non-small cell lung cancer. The goal is to see if these combinations are safe and can shrink tumors. About 324 adults aged 18-75 with good performance status are being enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Chest hospital
RECRUITINGShanghai, Shanghai Municipality, 200030, China
Contact
-
Zhejiang Cancer Hospital
RECRUITINGHangzhou, Zhejiang, 310022, China
Contact
Conditions
Explore the condition pages connected to this study.